Bank of Montreal Can reduced its holdings in Cambrex Co. (NYSE:CBM) by 9.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,320 shares of the biotechnology company’s stock after selling 3,301 shares during the period. Bank of Montreal Can owned approximately 0.10% of Cambrex worth $1,551,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its holdings in Cambrex by 1.0% in the third quarter. Dimensional Fund Advisors LP now owns 1,343,468 shares of the biotechnology company’s stock valued at $73,891,000 after buying an additional 13,214 shares during the period. State Street Corp raised its holdings in Cambrex by 5.1% in the second quarter. State Street Corp now owns 779,820 shares of the biotechnology company’s stock worth $46,600,000 after purchasing an additional 37,669 shares during the period. American Capital Management Inc. raised its holdings in Cambrex by 11.4% in the third quarter. American Capital Management Inc. now owns 565,658 shares of the biotechnology company’s stock worth $31,111,000 after purchasing an additional 57,770 shares during the period. Boston Partners acquired a new stake in Cambrex in the third quarter worth $17,869,000. Finally, Ameriprise Financial Inc. raised its holdings in Cambrex by 6.0% in the third quarter. Ameriprise Financial Inc. now owns 313,817 shares of the biotechnology company’s stock worth $17,260,000 after purchasing an additional 17,636 shares during the period.
Shares of Cambrex Co. (NYSE CBM) opened at $53.50 on Thursday. The firm has a market cap of $1,750.00, a price-to-earnings ratio of 17.26, a price-to-earnings-growth ratio of 1.24 and a beta of 2.38. Cambrex Co. has a twelve month low of $42.55 and a twelve month high of $62.95.
CBM has been the topic of several analyst reports. Craig Hallum reiterated a “buy” rating and issued a $60.00 target price (down from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. Zacks Investment Research upgraded shares of Cambrex from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th. William Blair initiated coverage on shares of Cambrex in a report on Tuesday, January 16th. They issued an “outperform” rating on the stock. Finally, Longbow Research lowered shares of Cambrex from a “buy” rating to a “neutral” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $60.00.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.